Schonfeld Strategic Advisors LLC - JUNO THERAPEUTICS INC ownership

JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 180 filers reported holding JUNO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.57 and the average weighting 1.2%.

Quarter-by-quarter ownership
Schonfeld Strategic Advisors LLC ownership history of JUNO THERAPEUTICS INC
ValueSharesWeighting
Q4 2017$3,106,000
+694.4%
67,954
+679.0%
0.25%
+605.6%
Q3 2017$391,000
-13.5%
8,723
-57.2%
0.04%
-20.0%
Q1 2017$452,000
+17.4%
20,376
+103.0%
0.04%
-47.7%
Q2 2016$385,00010,0390.09%
Other shareholders
JUNO THERAPEUTICS INC shareholders Q2 2016
NameSharesValueWeighting ↓
Biomark Capital Management Co. LLC 2,168,601$65,080,00086.12%
Crestline Management, LP 17,348,799$520,637,00066.02%
Omega Fund Management, LLC 1,229,512$36,898,00028.17%
SIB LLC 100,000$3,001,0002.42%
Clarius Group, LLC 117,896$3,538,0001.65%
BB BIOTECH AG 1,405,000$42,164,0001.48%
Duquesne Family Office 493,000$14,795,0001.31%
First Washington CORP 65,320$1,960,0001.10%
PFM Health Sciences, LP 1,124,285$33,740,0000.99%
Partner Investment Management, L.P. 18,376$551,0000.82%
View complete list of JUNO THERAPEUTICS INC shareholders